Avastin (bevacizumab) / Roche - LARVOL DELTA

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) (clinicaltrials.gov) - P3 | N=643 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial primary completion date: Jun 2025 ➔ Mar 2025

Platinum resistant • Trial primary completion date • Fallopian Tube Cancer • Gynaecologic Neuroendocrine Carcinoma • Oncology • Ovarian Cancer • Solid Tumor

Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC (clinicaltrials.gov) - P2 | N=44 | Not yet recruiting | Sponsor: Fujian Cancer Hospital

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor • BRAF

Comparison analysis of different doses bevacizumab plus ICIs and interventional therapy in unresectable hepatocellular carcinoma: a real-world study. (PubMed, J Gastrointest Oncol) - "Although full-dose bevacizumab in triple therapy showed prolonged PFS compared to half-dose group, no statistically significant differences were observed in long-term survival outcomes or treatment-related AEs between the two groups. For unresectable HCC patients with severe liver cirrhosis, half-dose bevacizumab may serve as a safer alternative without compromising survival benefits."

Journal • Real-world evidence • Fibrosis • Gastroenterology • Hepatocellular Cancer • Hepatology • Immunology • Liver Cirrhosis • Oncology • Solid Tumor

Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report. (PubMed, J Gastrointest Oncol) - "Immunotherapy in hepatocellular carcinoma (HCC) has changed the clinical practice for unresectable and advanced setting after the approvals of atezolizumab plus bevacizumab and durvalumab plus tremelimumab (STRIDE regimen)...A 61-year-old man with a diagnosis of advanced hepatocellular carcinoma (aHCC) (abdominal lymph nodes, lung, mediastinal nodes, bone) in the setting of alcoholic cirrhosis with a history of esophageal varices was treated with single-agent nivolumab 480 mg intravenous (IV) every four weeks for approximately 17 months (18 cycles) with partial response (PR)...LT in patients with aHCC with CR to immunotherapy may be feasible and safe in carefully selected patients, potentially curing the underlying liver disease, which impacts both survival and quality of life. However, the immunosuppressive state induced by LT may facilitate the disease progression of extrahepatic disease, therefore this should be considered only in selected patients with a prolonged CR..."

Journal • Fibrosis • Gastroenterology • Hepatocellular Cancer • Hepatology • Immunology • Liver Cancer • Oncology • Solid Tumor • Transplantation

A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer. (PubMed, EClinicalMedicine) - P2 | "Patients received tislelizumab (200 mg), bevacizumab (7.5 mg/kg), paclitaxel (175 mg/m2), and cisplatin (50 mg/m2) or carboplatin (AUC = 5) on day 1 of cycle 1 (every 3 weeks) in safety run-in stage. This work was supported by grants from the Pioneer R&D Program of Zhejiang (2023SDYXS0001, 2022C03031) and by BeiGene (Beijing) Co., Ltd. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Journal • P2 data • Cervical Cancer • Hematological Disorders • Oncology • Renal Disease • Solid Tumor

Depth of Response Predicts Survival in Unresectable Hepatocellular Carcinoma Treated with Immunotherapy: Not All Stable Disease Is Equal. (PubMed, Liver Cancer) - No abstract available

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients (clinicaltrials.gov) - P2 | N=162 | Not yet recruiting | Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

New P2 trial • Colorectal Cancer • Neutropenia • Oncology • Solid Tumor

IGF-2-Mediated Hypoglycemia in a Patient with Newly Diagnosed Metastatic Sarcoma: A Rare Paraneoplastic Syndrome (ENDO 2025) - "Subsequently, chemotherapy with temozolomide and bevacizumab was initiated...Hypoglycemia is managed with supportive measures via corticosteroids, diazoxide, glucagon infusion pumps, recombinant growth hormone or dextrose fluids. IGF-2 mediated hypoglycemia is a rare paraneoplastic syndrome seen in malignancies such as sarcomas or hepatoblastomas. Hypoglycemia occurs due to overproduction of IGF-2 by the tumor which has insulin like-effects. Unlike insulin-mediated hypoglycemia, IGF-2-induced hypoglycemia occurs in the absence of insulin or C-peptide."

Clinical • Metastases • Cardiovascular • Diabetes • Hepatoblastoma • Hepatology • Hypertension • Hypoglycemia • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor • IGF1 • IGF2

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor

Challenges in Endocrine Function Testing During Clinical Cancer Drug Trials: False Positives Due to Heterophilic Antibodies (ENDO 2025) - "She was referred to the Endocrinology Department for osteoporosis management, and after evaluation, she was treated with Denosumab and cholecalciferol...Two months after switching to alendronate, PTH was measured at 1171 pg/mL...Following the initiation of osteoporosis treatment, the patient participated in a clinical trial to assess the safety and efficacy of Oregovomab in combination with Paclitaxel, Carboplatin, and Bevacizumab... Heterophilic antibodies have been recognized for a long time, but caution is needed as mouse-derived antibodies are still used in early-stage research. These antibodies can cross-react with non-homologous antigens, interfere with immunoassays, and lead to inaccurate test results."

Clinical • Endocrine Disorders • Oncology • Ovarian Cancer • Pituitary Gland Carcinoma • Rheumatology • Solid Tumor

Checkpoint Inhibitor Therapy and Adrenal Insufficiency: The Critical Role of ACTH Measurement (ENDO 2025) - "She had a history of cervical adenocarcinoma treated with carboplatin/paclitaxel/bevacizumab plus pembrolizumab for 11 months...Peak cortisol after cosyntropin 7.3 ug/dL. She was started on hydrocortisone and later fludrocortisone due to potassium on the higher end of normal... The adverse events associated with ICI is unpredictable. The diagnosis of AI is challenging in these patients because nonspecific symptoms can be attributed to side effects from chemo or immunotherapy. Our patient presented with common features of primary AI."

Checkpoint inhibition • Cervical Adenocarcinoma • Cervical Cancer • Endocrine Disorders • Fatigue • Nephrology • Oncology • Renal Disease • Solid Tumor

ICT-HCC: Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Nanjing Tianyinshan Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis. (PubMed, Front Pharmacol) - "Immune checkpoint inhibitors (ICIs) combined with etoposide-platinum are recommended as the standard first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)...The drug combination patterns included ipilimumab, durvalumab, adebrelimab, atezolizumab, socazolimab, pembrolizumab, serplulimab, tislelizumab, toripalimab, durvalumab + tremelimumab, tiragolumab + atezolizumab, benmelstobart + anlotinib, bevacizumab + atezolizumab, anlotinib, bevacizumab in combination with chemotherapy...The toxicity of ICI + Antiangio + Chemo was acceptable but needed careful attention. These findings clarified the roles of ICIs and antiangiogenic agent-based treatment strategies in this population."

Journal • Retrospective data • Review • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma (clinicaltrials.gov) - P=N/A | N=1 | Active, not recruiting | Sponsor: Daniela A. Bota | N=34 ➔ 1

Enrollment change • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Oncology • Solid Tumor • ATRX

The impact of bevacizumab on port catheter complications: A retrospective evaluation in cancer patients. (PubMed, J Oncol Pharm Pract) - "Multivariable logistic regression analysis revealed that leukemia was a significant independent factor for increased complication risk (p < 0.001), while comorbidities were protective against complications (p = 0.030).ConclusionBevacizumab was associated with increased complication risk in only subjects in which treatment was initiated immediately after catheter placement. However, multivariable analysis revealed that this significant relationship disappeared when adjusted for other factors, leaving leukemia as the only risk factor independently associated with port catheter complications."

Journal • Retrospective data • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology

Corneal melting following intrastromal injection of bevacizumab for corneal neovascularization. (PubMed, Oman J Ophthalmol) - "A week later developed corneal melting. In conclusion, anti-VEGF can be used in controlling corneal neovascularization, albeit, is associated with risks such as delayed epithelial healing and corneal melting, particularly in those with limbal stem cell deficiency."

Journal • Infectious Disease • Measles • Ophthalmology • Transplant Rejection • Transplantation

Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study. (PubMed, J Neurooncol) - "A subgroup of GBM patients responds to BevCT up to three times in the recurrent setting, and these repeated responders exhibit prolonged survival. No definitive prognostic variables or histopathological features were found in this study. Further investigation into the downregulation of HILPDA and IGF2, along with high AGT promoter methylation levels and other potential predictive biomarkers, is warranted to better understand the mechanisms underlying repeated BevCT response."

Journal • Retrospective data • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • IGF2

Personalized risk stratification in colorectal cancer via PIANOS system. (PubMed, Nat Commun) - "Moreover, PIANOS discriminates treatment responses across risk categories, with high-risk patients showing increased sensitivity to bevacizumab and low-risk patients exhibiting enhanced responsiveness to chemotherapy and immunotherapy. This study reports significant advancements in supporting clinical decision-making for CRC and provides a reliable framework for optimizing patient treatment strategies."

Biomarker • IO biomarker • Journal • Colorectal Cancer • Oncology • Solid Tumor

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment. (PubMed, Oncotarget) - "We present a 62-year-old male with mCRC harboring BRAF, MET, APC, TP53 and NRAS alterations, following FOLFOX and FOLFIRI, dabrafenib plus panitumumab, and a BRAF inhibitor clinical trial, each leading to initial responses followed by disease progression...Personalized combinations suggested included amivantamab-vmjw (anti-MET/EGFR antibody) (one-third standard dose) (for MET amplification and due to prior response to anti-EGFR antibody), trametinib, 1 mg po daily (MEK inhibitor for BRAF V600E mutation), and regorafenib (may have WNT inhibitor activity relevant to APC mutation; VEGFR activity relevant since TP53 alterations upregulate VEGF/VEGFR axis) starting at 40 mg po daily three weeks on, one week off. Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily. FOLFOXFIRI combined with bevacizumab, or liver-directed therapies for hepatic metastases, or..."

Biomarker • Journal • Colorectal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • APC • NRAS • TP53

Rechallenging Unresectable Hepatocellular Carcinoma with the STRIDE Regimen: A Case Report of Significant AFP Response after Atezolizumab-Bevacizumab Intolerance. (PubMed, Case Rep Oncol) - "However, limited data exist on rechallenging patients with alternative ICI regimens, such as STRIDE (durvalumab + tremelimumab), following initial treatment failure or intolerance to atezolizumab + bevacizumab. This case suggests that rechallenging with the STRIDE regimen may provide significant clinical benefit in HCC patients intolerant to initial ICI therapy. However, further clinical trials are needed to confirm the efficacy and optimal use of ICI rechallenge strategies in HCC."

Journal • Cardiovascular • Fibrosis • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Immunology • Infectious Disease • Oncology • Solid Tumor • Thrombosis

Long-Term Assessment of Choroidal Thickness and Refractive Outcomes in Patients Treated for Retinopathy of Prematurity: A Case Control Study. (PubMed, Ophthalmic Surg Lasers Imaging Retina) - "Pediatric patients who previously required treatment for ROP had lower choroidal thickness and a greater degree of myopia compared to those without ROP. No significant difference was seen in refractive or structural outcomes when comparing laser, anti-VEGF, and a combination therapy. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.]."

Journal • Ophthalmology • Pediatrics • Retinal Disorders • Retinopathy of Prematurity

Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report. (PubMed, Front Immunol) - "This report presents the case of a 45-year-old Chinese woman with advanced PLCNEC who received first-line treatment with a four-drug regimen consisting of etoposide, cisplatin, camrelizumab, and endostar...Second-line therapy with atezolizumab, bevacizumab, and docetaxel achieved a PFS2 of 1 year. Third-line treatment maintained atezolizumab and introduced the anti-angiogenic agent anlotinib and chemotherapeutic agent pemetrexed, resulting in a PFS3 of 6 months...This case illustrates the potential for long-term survival in advanced PLCNEC through intensive, multi-line combination therapies. The favorable outcome observed in this patient supports further investigation of such combination strategies in clinical studies."

Journal • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer. (PubMed, Front Oncol) - "This study aimed to evaluate the efficacy and safety of cadonilimab(PD-1/CTLA-4 bispecific)with anti-angiogenesis adjuvant therapy (bevacizumab or anlotinib) in pretreated patients with r/mCC...The findings suggest that this regimen might be potentially efficacious and safe with relatively manageable toxicity. Further trials with a control arm are required to validate our findings."

Journal • Cardiovascular • Cervical Cancer • Hypertension • Oncology • Renal Disease • Solid Tumor • CTLA4 • PD-1

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study (clinicaltrials.gov) - P2 | N=74 | Recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P2 trial • Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Participants' perspectives of the advanced ovarian cancer biomarker study VALTIVE1: a qualitative study. (PubMed, BMJ Open) - P=N/A | "A future trial should consider ensuring all participants have access to test results, as participants indicated a preference to know whether bevacizumab was working and to discontinue bevacizumab if it had not prevented tumour growth based on the biomarker results. Comprehensive and ongoing information and support regarding treatment side effects should be provided to all participants throughout their cancer pathways and trials."

Biomarker • Journal • Fatigue • Gynecologic Cancers • Oncology • Ovarian Cancer • Pain • Solid Tumor